Status:
COMPLETED
Phase II Trial of RAD001 in Refractory Colorectal Cancer
Lead Sponsor:
Swedish Medical Center
Collaborating Sponsors:
Novartis
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Single center open-label study of an oral agent (RAD001) in subjects with metastatic colorectal cancer refractory to at least 2 standard chemo/biologic regimens.
Detailed Description
Study is completed and closed.
Eligibility Criteria
Inclusion
- Metastatic colorectal cancer refractory to at least 2 chemo/biologic regimens
- Measurable disease
- ECOG 0-2
Exclusion
- CNS disease
- Chemotherapy or radiotherapy \< 4 weeks prior
- Active bleeding diathesis
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2007
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00337545
Start Date
May 1 2006
End Date
April 1 2007
Last Update
October 10 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Swedish Cancer Institute
Seattle, Washington, United States, 98104